The importance of these non-BCR effects on clinical responses to BCR inhibitor treatment in B cell malignancies other than CLL are less certain at present, although similar effects on malignant cell migration and adhesion have been reported in MCL and WM [30,186]. This evidence concerns the gene BCR and mantle cell lymphoma.